European Archives - Page 225 of 899 - European Medical Journal

26th October 2022

Recent Advances in the First-Line Management of Advanced Renal Cell Carcinoma: Focus on the Role of Lenvatinib Plus Pembrolizumab Combination Treatment

The 37th Annual European Association of Urology (EAU) Congress 2022 in Amsterdam, the Netherlands, where data from the CLEAR study, a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab combination therapy against sunitinib as first-line treatment in patients with advanced renal cell carcinoma, were presented.

25th October 2022

Expert Insights into Paediatric Tuberculosis

The first podcast in this three-part series introduces the topic of paediatric tuberculosis (TB) and the concept of latent TB infection (L TBI). Statistics on the risk of progression from LTBI to active TB, as well as the risk of severe TB disease, dissemination, and death in children versus adults are shared.

Driving confidence and participation in genetic research

In this episode, Helena and Isabel are joined by Patrick Short, CEO, Sano Genetics, to discuss the challenges and opportunities facing genetic medicine.

25th October 2022

Striving for more: personalizing care in patients with psoriatic disease

Striving for more: personalizing care in palients with psoriatic disease. Educational objectives: Understand what patients need and expect from their treatment journey from its outset. Drive the importance of collecting patient reported outcomes on registries and analysing data by gender/age. Consider shared decision-making as essential throughout a patient’s joumey, understanding how it can further treatment personalisation and patient outcomes

25th October 2022

Tumour Organoids from Multifocal Metastatic Colorectal Cancers for Personalised Oncology

Patients with colorectal cancer (CRC) have limited systemic treatment options compared to other major cancer types.1 Tumour heterogeneity is a major cause of treatment failure.

25th October 2022

Review of the European Society for Medical Oncology (ESMO) Congress 2022

THREE years after the last in-person European Society for Medical Oncology (ESMO) Congress, the 2022 congress welcomed nearly 23,000 participants in Paris, France, as well as 5,000 online. The purpose of the congress was a celebration of being back together, and of collaboration between all healthcare professionals wanting to improve survival times for patients.

EMJ Oncology 10.1 2022

The latest issue of EMJ Oncology is out now featuring engaging content, including a review article examining colorectal cancer during pregnancy and an analysis of optimal immunohistochemical cut-off markers in breast cancer.

25th October 2022

Precision Medicine and Next-Generation Sequencing Diagnostic at European Society for Medical Oncology Congress 2022: The Unbreakable Bond

This article covers symposia that took place from 9th–13th September, 2022 as part of the European Society for Medical Oncology (ESMO) Congress 2022.

25th October 2022

Does Hepatitis C Independently Increase the Risk of Colorectal Adenoma?

Hepatitis C virus (HCV) infection has been associated with extrahepatic malignancies such as colorectal carcinoma (CRC). The majority of CRCs arise from adenomatous polyps, and it is not known if HCV infection influences the growth of these pre-cancerous lesions.

25th October 2022

Immunotherapy in Non-small Cell Lung Cancer: Current and Future Use

EXPLORING the current state of use of immunotherapies in the treatment of non-small cell lung cancer (NSCLC) and looking to future immunotherapeutic pathways, three expert speakers presented a session at European Society for Medical Oncology (ESMO) Congress 2022, on the 12th of September.